AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease

Announced strategic acquisition of industry-leading Parkinson's disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS)

AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson's Disease at AAIC 2021

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline

BioNTech SE

AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 million private share placement with a group of investors led by Athos Service GmbH.

AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate

VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS' anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

All-stock transaction maintains AC Immune's strong cash position

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.

AC Immune Holds its Annual General Meeting of Shareholders

The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 20% pre-market. This is why it happened.

ACIU Stock Price: Over 20% Increase Pre-Market Explanation

AC Immune SA (NASDAQ: ACIU) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirming earlier interim results.

AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile

Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates

AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively.

AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor Conferences

AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD). The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose.

AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate

AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates

LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021.

AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade

Dr. Colowick has more than 20 years of experience in large and emerging biotech companies

AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors

Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics

AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease

Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases

AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline

ACIU is developing drugs for Alzheimer's disease.

AC Immune: Old Theory, New Company

Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to ($0.28), which missed the estimate of ($0.27).

Recap: AC Immune Q4 Earnings

LAUSANNE, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020. The Company also provided an overview of its execution strategy and anticipated clinical and preclinical milestones for 2021, as well as the strong progress being made across its broad portfolio of therapeutic and diagnostic product candidates.

AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook

Can-Fite BioPharma Ltd.

Moderna

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Why Can-Fite, Moderna, AC Immune Shares Are Rallying

Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.

News for AC Immune Stock (ACIU)